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a  b  s  t  r a  c t
Catheter-related bloodstream  infections (CRBSI)  constitute an important cause of hospital-acquired
infection  associated  with morbidity, mortality,  and cost. The aim of these  guidelines  is  to provide
updated  recommendations for  the  diagnosis  and  management  of CRBSI  in adults. Prevention  of  CRBSI
is  excluded. Experts in  the  field were  designated  by  the  two  participating  Societies  (Sociedad  Española
de Enfermedades  Infecciosas y  Microbiología  Clínica  and  the Sociedad Española de  Medicina  Intensiva,
Crítica  y  Unidades  Coronarias).  Short-term peripheral venous catheters,  non-tunneled  and long-term
central venous  catheters,  tunneled  catheters and hemodialysis catheters are  covered  by  these  guidelines.
 The consensus statement is available at: https://www.seimc.org/contenidos/documentoscientificos/guiasclinicas/seimc-guiasclinicas-2017-Catheter-Related Bloodstrea
m  Infection.pdf and as additional material in the journal official website.
 The complete consensus statement has also been published in:  Medicina Intensiva. 2017. http://dx.doi.org/10.1016/10.1016/j.medin.2017.09.012
∗ Corresponding author.
E-mail address: jdelpozo@unav.es (J.L. del Pozo).
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The panel  identified 39 key  topics that  were  formulated  in accordance with  the  PICO  format. The strength
of the  recommendations  and quality  of the  evidence  were graded  in  accordance with ESCMID  guidelines.
Recommendations  are  made for  the  diagnosis  of CRBSI  with and  without catheter  removal  and  of tunnel
infection.  The document  establishes  the  clinical situations  in which  a  conservative diagnosis  of CRBSI
(diagnosis  without  catheter  removal)  is feasible.  Recommendations  are  also  made regarding  empirical
therapy,  pathogen-specific treatment  (coagulase-negative  staphylococci,  Sthaphylococcus  aureus, Entero-
coccus  spp,  Gram-negative  bacilli,  and  Candida spp), antibiotic  lock therapy,  diagnosis  and management
of suppurative  thrombophlebitis  and local  complications.
© 2017  Elsevier España,  S.L.U. and  Sociedad Española  de  Enfermedades Infecciosas  y  Microbiologı́a
Clı́nica.  All rights  reserved.
Resumen  ejecutivo  del  documento  de  consenso  sobre  diagnóstico  y
tratamiento  de la bacteriemia  relacionada  con  catéter:  Guía  de Práctica  Clínica
de  la  Sociedad  Española  de Enfermedades  Infecciosas  (SEIMC)  y de  la  Sociedad
Española  de  Medicina  Intensiva  Crítica  y  Unidades  Coronarias  (SEMICYUC)
r  e  s  u  m e  n
La bacteriemia  relacionada  con catéteres  (BRC)  constituye  una  causa importante  de  infección hospitalaria
y  se asocia con  elevada  morbilidad,  mortalidad  y  costo. El objetivo de  esta  guía  de  práctica clínica  es
proporcionar  recomendaciones actualizadas  para el  diagnóstico  y  el tratamiento  de  la BRC en  pacientes
adultos.  De  este  documento  se excluye  la  prevención  de  la  BRC.  Expertos en la materia fueron  designados
por  las  2  sociedades  participantes  (Sociedad  Española de Enfermedades  Infecciosas  y  Microbiología Clínica
y  Sociedad Española  de  Medicina  Intensiva, Crítica  y  Unidades  Coronarias).  Los catéteres  venosos  periféri-
cos  a corto  plazo,  los catéteres  venosos centrales no  tunelizados  y  de  largo  plazo, los catéteres  tunelizados
y  los  catéteres  de hemodiálisis  están  incluidos  por  estas guías.  El panel identificó  39 temas claves que
fueron  formulados de  acuerdo  con  el  formato  PICO.  La fuerza  de  las  recomendaciones  y  la  calidad  de  la
evidencia  se clasificaron de  acuerdo  con las  directrices  de  la  ESCMID.  Se hacen recomendaciones  para  el
diagnóstico  de  BRC con y  sin  extracción  de  catéter y  de  la infección  en túnel.  El documento  establece las
situaciones  clínicas  en las  que es factible un diagnóstico  conservador de  CRBSI  (diagnóstico  sin retirada  de
catéter).  También  se hacen  recomendaciones  con respecto a  la terapia  empírica,  el  tratamiento  específico
según  el  patógeno  identificado  (estafilococos  coagulasa negativos, Staphylococcus  aureus,  Enterococcus
spp,  bacilos gramnegativos  y  Candida spp), la terapia  con sellado  del  catéter,  el  diagnóstico,  así como el
tratamiento  de  la tromboflebitis  supurativa y  las complicaciones  locales.
©  2017  Elsevier España, S.L.U. y  Sociedad Española de  Enfermedades Infecciosas  y  Microbiologı́a  Clı́nica.
Todos  los derechos  reservados.
Introduction: justification and aims
Intravascular devices have become an essential component of
modern medicine for the administration of intravenous fluids, med-
ication, blood products and parenteral nutrition and for monitoring
hemodynamic status and providing hemodialysis. According to
national data supplied by  the study of the prevalence of nosocomial
infections in Spain (EPINE), it is estimated that about 70% of patients
admitted to Spanish hospitals will wear one of these devices at
some point during their stay.1 Local or  systemic infections repre-
sent one of the main associated complications.2 The incidence of
catheter-related infections varies considerably depending on the
type and intended use, the insertion site, the experience and train-
ing of the individual who places the catheter, the frequency with
which the catheter is accessed, duration of catheter placement, the
characteristics of the patient, and the use of proven prevention
strategies. Catheter-related bloodstream infections (CRBSIs) are
among the most frequent infections acquired in  hospital. Current
estimates are that between 15 and 30% of all nosocomial bac-
teremias are catheter-related.3 CRBSIs have significant associated
morbidity, incur increased hospital costs,4 estimated at approxi-
mately 18,000 euros per episode, and length of stay.5 Attributable
mortality ranges between 12 and 25%.6 In recent years, there has
been a remarkable increase in  our knowledge of the epidemiology
of CRBSI and of the most appropriate methodologies for diagno-
sis, management and prevention. The vast amount of information
accumulated and the inherent complexity of this type of infection
make it necessary to  sort and analyze the available information. At
the same time, there are few current guidelines available on this
topic. The last Spanish catheter-related infections guidelines were
published in 2004.7 The aim of this new guide is  to update recom-
mendations for the diagnosis and management of catheter-related
bloodstream infections. This document targets only microbiologi-
cal diagnosis and antimicrobial therapy; other aspects of infection
management and prevention are therefore excluded. Only adult
patients with these infections are covered.
Methods
The two participating Societies (Sociedad Española de Enfer-
medades Infecciosas y Microbiología Clínica and the Sociedad
Española de Medicina Intensiva, Crítica y Unidades Coronar-
ias) nominated three coordinators for this project (FC, JGM and
JLdP: a  microbiologist, an intensivist, and an infectious disease
physician). This coordinating group selected the rest of  the mem-
bers of the panel, including microbiologists, intensivists, and
infectious disease physicians. The Scientific Committees of  both
Societies approved their proposal. The present Statement was
written following the SEIMC guidelines for consensus statements
(www.seimc.org) as well as the recommendations of  the AGREE
Collaboration (www.agreecollaboration.org)  for evaluating the
methodological quality of clinical practice guidelines. The strength
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Table 1





A Strongly supports a  recommendation for use
B  Moderately supports a  recommendation for use
C  Marginally supports a  recommendation for use
D  Supports a  recommendation against use
Quality of evidence
I  Evidence from at least one properly designed
randomized, controlled trial
II  Evidence from at least one well-designed clinical trial,
without randomization; from cohort or
case-controlled analytic studies (preferably from
1  center); from multiple time series; or from dramatic
results of uncontrolled experiments
III Evidence from opinions of respected authorities, based
on clinical experience, descriptive case studies
of the recommendations and quality of the evidence were graded
in accordance with ESCMID guidelines (Table 1).
The coordinating group identified 39 key topics that were
formulated in accordance with the PICO format defining the pop-
ulation, intervention, comparator, and outcome of interest. These
key questions were approved by  the Scientific Committees of both
Societies and then distributed to the different members of the panel
(2 or 3 questions each) for further development. The coordinat-
ing group wrote the first draft based on the sections submitted
by each participant, which was then sent to the panel for criti-
cal  review. Before its final approval, the document was published
on the intranet of both  Societies and left open to  suggestions and
comments from members. All authors and coordinators of the
Statement have agreed the contents of the document and the final
recommendations.
General aspects
When should catheter-related bloodstream infection be sus-
pected?
Recommendations:
• CRBSI should be suspected in patients with intravenous catheters
and fever, chills or other signs of sepsis, even in the absence of
local signs of infection, and especially if no alternative source is
identified (A-III).
• Clinical suspicion of CRBSI should also increase in  patients with
intravenous catheters who have metastatic infections caused by
hematogenous spread of microorganisms (i.e. septic emboli) (A-
III).
• Persistent or recurrent bacteremia caused by microorganisms
that tend to colonize or infect the skin in  patients with intra-
venous catheters should lead to suspicion of CRBSI (A-III).
How is a complicated catheter-related bloodstream infection
defined?
Recommendations:
• Patients with CRBSI with endocarditis, suppurative throm-
bophlebitis, septic metastasis, extraluminal infections, septic
shock, non-resolving CRBSI, and immunocompromised patients
should be categorized as complicated CRBSI (A-III).
Diagnosis without catheter withdrawal (conservative diagnosis)
How should blood cultures be taken?
Recommendation:
• Obtain blood cultures using an aseptic technique before the ini-
tiation of antimicrobial therapy (A-I)
• Skin preparation for obtaining blood samples drawn percuta-
neously should be  performed with proper techniques, including
the time to perform the procedure and leaving adequate time
for the disinfectant to take effect (A-I). Alcohol-containing
products are associated with low rates of contamination. Alcohol-
chlorhexidine solutions reduce blood culture contamination
more efficiently than aqueous povidone-iodine (A-I).
• In patients with suspected CRBSI, two  pairs of blood cultures
should be drawn, one from a  peripheral vein and the other from
the catheter (A-I).
• For multiple-lumen venous catheters, samples for blood culture
should be obtained from all lumens (A-II).
How should conventional blood cultures be interpreted?
Recommendation:
• For diagnosis of CRBSI, positivity of blood cultures obtained
through the catheter ≥120 min  before those from a peripheral
vein with the same microorganism is highly suggestive. An opti-
mal  DTP cut-off for the diagnosis of catheter-related candidemia
has not been established. (A-II).
• The interpretation of DTP should consider adherence to the pro-
cedural technique used and the type of microorganism (A-II).
• Rapid microbial identification by MALDI-TOF MS from a  posi-
tive blood culture significantly reduces time to identification of
microorganisms and has clinical impact on the management of
patients with suspected bloodstream infection (A-II).
How should quantitative blood cultures be taken and inter-
preted?
Recommendation:
• A quantitative blood culture with a  colony count 3 times greater
in a  sample drawn through a catheter than from the peripheral
vein supports a  diagnosis of CRBSI (A-II). This method is  less prac-
ticable for routine use.
What particular aspects should be considered for the diag-
nosis of CRBSI in patients on hemodialysis?
Recommendations:
• Whenever possible, paired blood samples from the CVC and
a peripheral vein should be obtained for a CRBSI diagnosis in
hemodialysis patients (A-II).
• Peripheral blood samples should be obtained from veins that are
not intended for future creation of dialysis fistulae or grafts. The
veins of the hand for outpatients and hand or femoral veins for
hospital inpatients should be used to  obtain peripheral blood
cultures (A-III).
• If a  blood sample cannot be drawn from a peripheral vein, two
separate samples should be drawn, 10–15 min  apart, through the
CVC or  the dialysis circuit connected to  the catheter (B-II).
What is the present value of molecular techniques for the
diagnosis of CRBSI?
Recommendations:
• At the present time, there is not enough information to rec-
ommend implementing these techniques in clinical practice for
CRBSI diagnosis (C-II).
Diagnosis of CRBI with catheter withdrawal
When should a catheter tip be sent for culture?
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Recommendations:
• Catheter cultures should only be obtained when catheter-related
bloodstream infection is suspected (A II).
How should a  catheter be sent and processed in  the Microbi-
ology Laboratory?
Recommendations:
• The most reliable diagnostic methodologies are  the semiquanti-
tative (roll plate) or  quantitative (vortex or  sonication methods)
catheter culture techniques (A-II).
• Qualitative cultures (culture of the catheter tip by  broth immer-
sion) are unreliable for distinguishing between contamination
and infection and are  not therefore suitable for the diagnosis of
CRBSI (A-II).
How should the results of catheter cultures be interpreted?
Recommendations:
• The presence of 15 CFU per plate or  more by  semiquantitative cul-
ture (roll-plate) is  indicative of significant catheter colonization
(A-II).
• For quantitative culture methods based on  vortexing or flushing
the internal surface, a  count of 103 CFU/segment or more reflects
significant catheter colonization (A-II).
• For  quantitative culture methods based on sonication, counts
above 102 CFU/segment indicate significant catheter colonization
(A-II).
How should a  subcutaneous reservoir be processed?
Recommendations:
• Venous access devices removed for suspected CRBSI should be
sent to the microbiology laboratory. Routine processing should
include a combination of cultures from different parts of the VAD,
including a culture after septum sonication and semiquantitative
catheter tip cultures (B-II).
What other conservative techniques may be used for diagno-
sis of CRBSI?
Recommendation:
• Endoluminal brushing of the internal surface of the catheter
may  be useful for diagnosis of CRBSI. However, the procedure
is impractical and major side-effects have been reported (C-III).
• Semiquantitative cultures of skin around the catheter insertion
site and catheter hubs with ≥15 cfu may  be  indicative for CRBSI.
These procedures must be combined with peripheral blood cul-
ture (B-II).
• Gram stain – acridine orange leukocyte cytospin (AOLC) of
catheter blood may  be used as a rapid method for diagnosis of
CRBSI. The presence of any microorganisms in a  minimum of 100
high-powered fields may  be indicative of CRBSI (B-II).
What is the value of molecular techniques for the diagnosis
of CRBSI after catheter removal?
Recommendation:
• 16S rRNA PCR could be performed with septum sonication fluid
to rule out or confirm VAD-RBSI in patients undergoing antibiotic
therapy (C-III).
Diagnosis of local signs of infection
What samples should be taken and how should they be inter-
preted when an insertion site infection is suspected?
Recommendations:
• When catheter infection is suspected and there is exudate at the
catheter insertion site, it should be sent for Gram staining and
culture. Blood cultures should also be drawn (A-III).
• In patients with suspected catheter-related infection but negative
superficial cultures (growth of <15 CFU from both the insertion
site and catheter hub cultures), the possibility of infection can
reasonably be ruled out (B-II).
Catheter related bloodstream infection treatment
When can a catheter be retained until blood cultures are
available?
Recommendation:
• Immediate removal of the CVC is  not  routinely recommended
when CRBSI is  suspected in  patients who are hemodynamically
stable, without autoimmune diseases or immunosuppressive
therapy, intravascular foreign bodies or organ transplants, no
suppuration at the insertion site  or bacteremia/fungemia (A-I).
When is  it safe to perform a catheter exchange over a
guidewire?
Recommendations:
• Routine replacement of a CVC by guidewire exchange is  not rec-
ommended because this strategy is  associated with a  higher risk
of infectious complications. (B-II)
• Guidewire exchange of a  CVC  is contraindicated in patients with
documented catheter infections. (A-II)
• Guidewire exchange should be restricted to  patients with very
difficult venous access (i.e. extensive burns, morbid obesity, or
severe coagulopathy) and without documented catheter infec-
tion (B-II). In this case, a  meticulous aseptic technique and a
culture of the catheter tip are mandatory. (A-III)
• If the catheter tip culture is positive, the new line, inserted over
a guidewire, should be re-placed via a  new direct venipuncture.
(C-III)
What should be done if the catheter tip culture is positive but
the blood cultures are negative?
Recommendations:
• Antibiotic treatment (i.e. 5–7 days) should be given to patients
with catheter tip cultures positive for S. aureus and negative blood
cultures if the patient shows systemic signs of infection or signs
of local infection (B-II).
• In non-neutropenic patients or those without valvular heart
disease, the presence of a  catheter tip culture positive for Can-
dida spp. and negative or unavailable blood cultures should be
assessed on an individual basis before starting systematic anti-
fungal treatment. Antifungal treatment should not  be prescribed
for patients without systemic signs of infection (B-II).
• No clear recommendations can be  given for catheters colonized
with other microorganisms (C-III).
Empirical antimicrobial therapy
What is  the empirical antimicrobial therapy for CRBSI?
Recommendations:
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• If  CRBSI is suspected, antimicrobial therapy should be  started as
soon as possible with a  bactericidal agent active against S. aureus
and CoNS, especially if associated with sepsis or  septic shock (B-
II).
• Vancomycin is  recommended for empirical therapy in patients
with suspected CRBSI (B-II). Teicoplanin is  not recommended
as empirical therapy, given the existence of coagulase-negative
staphylococci with reduced susceptibility to  teicoplanin (C-III).
• Daptomycin can be administered for cases of CRBSI with septic
shock (C-III), acute kidney injury (B-III), to  patients with recent
exposure to vancomycin (>1 week in the past 3 months) (C-III)
or  if the local prevalence of S. aureus isolates with vancomycin
MIC  ≥ 2.0 g/ml is  high (C-III). The local prevalence of S. aureus
isolates with vancomycin MIC  ≥ 1.5 g/ml supporting routine
empirical use of daptomycin remains undefined.
• Linezolid should only be used in  patients with contraindications
for the previous agents (B-II).
When should empirical coverage of Gram-negative bacilli or
fungi be added?
Recommendations:
• Patients with suspected CRBSI should receive empirical antibiotic
therapy (in addition to  coverage for Gram-positive pathogens) to
cover Gram-negative bacilli under any of the following circum-
stances: hemodynamic instability (septic shock), neutropenia or
hematologic malignancy, solid organ or bone marrow transplant,
femoral catheter in place, a high index of colonization with Gram-
negative bacilli or prolonged ICU admission (C-III).
• Antimicrobial therapy should be adapted to local epidemiology
and must include an antipseudomonal agent (piperacillin-
tazobactam, carbapenems, a  fourth-generation cephalosporin,
aztreonam, quinolones or aminoglycosides) (A-II). Aztreonam
and cephalosporins should be avoided in patients with colo-
nization or at risk for extended-spectrum -lactamase infections
(A-I).
• The need for empirical antifungal therapy in a  patient with sus-
pected catheter-related candidemia should be  evaluated along
with the possibility of catheter removal (A-III).
• Empirical therapy for suspected catheter-related candidemia
should be considered in  patients who are hemodynamically
unstable with one or more of the following conditions: total par-
enteral nutrition, prolonged use of broad-spectrum antibiotics,
malignancy, femoral catheterization, colonization due to Can-
dida species at multiple sites or intense previous anti-anaerobic
therapy (C-III).
• The use of biomarkers (such as 1,3-beta-D-glucan) may  be useful
when considering initiation of empirical treatment (B-III).
What particular aspects should be considered in the empiri-
cal treatment of CRBSI in patients on  hemodialysis?
Recommendation:
• Conservative management of CRBSI should be attempted
with hemodialysis patients. Combining systemic and local
intracatheter antibiotics is associated with improved results com-
pared to systemic antibiotics alone (A-I).
• In patients with a  tunneled hemodialysis catheter, guidewire
exchange is an  alternative, especially when catheter removal is
not feasible (C-III).
Targeted antimicrobial therapy
What is the recommended directed therapy and optimal
duration of treatment for CRBSI due to  Staphylococcus aureus?
Recommendations:
• The treatment of choice for an episode of MSSA CRBSI is  cloxacillin
or cefazoline (B-I).
• Patients allergic to beta-lactams should be treated with dapto-
mycin (A-I) or  a  glycopeptide (B-II).
• The best antimicrobial treatment for episodes caused by
MSSA strains with reduced susceptibility to vancomycin
(MIC ≥ 1.5 mg/L measured by E-test) has not been elucidated. This
panel suggests using a combination of cloxacillin and daptomycin
when blood cultures remain positive and/or there is no obvious
clinical improvement after catheter removal (C-III).
• Vancomycin is  the treatment of choice for CRBSI caused by MRSA
(B-II). Teicoplanin may  be a valid alternative, especially in  cases of
serious side effects associated with the use of vancomycin. (C-III)
• Alternatively, patients may  be treated with daptomycin, specifi-
cally if the MIC measured by E-test is  ≥1.5 mg/L (A-I).
• Linezolid should only be used in  patients when the previous
agents are  contraindicated (C-III).
• In both MSSA and MRSA CRBSI, blood cultures should be obtained
after 72 h of antibiotic therapy (C-III).
What is the recommended directed therapy and optimal
duration of treatment for CRBSI due to  coagulase-negative
Staphylococcus (CoNS)?
Recommendations:
• Cloxacillin or cefazolin are the treatments of choice for episodes
of CRBSI caused by CoNS susceptible to methicillin (B-I).
• For CoNS resistant to methicillin, a  glycopeptide is the treatment
of choice for directed therapy (B-II). Teicoplanin is recommended
in the case of serious side  effects associated with vancomycin.
(C-III).
• The optimal trough concentration of vancomycin for the treat-
ment of CoNS CRBSI is  an unresolved issue and this panel cannot
issue a  specific recommendation (C-III).
• S. lugdunensis CRBSI should be  managed as for S  aureus CRBSI
(C-III).
What is the recommended directed therapy and its optimal
duration for CRBSI due to  Enterococcus spp.?
Recommendations:
• Enterococcal CRBSI should be treated with catheter withdrawal
and one active antimicrobial (A-III).
• Ampicillin is  the drug of choice for susceptible isolates (A-II). Van-
comycin should be reserved for isolates resistant to ampicillin or
cases of beta-lactam allergy. For vancomycin-resistant isolates or
severe adverse effects, linezolid is  preferred to  daptomycin (B-III).
• There is no  evidence that combination therapy is necessary if IE
has been properly ruled out (A-III).
• Despite data suggesting that duration of treatment may  be
shorter, the standard 7–14 day regimen continues to be recom-
mended (A-III).
What is the recommended directed therapy and its optimal
duration for CRBSI due to  Gram-negative bacilli?
Recommendations:
• Directed therapy for GN-CRBSI should be chosen on the basis of
the susceptibility results (C-III).
• The appropriate length of antimicrobial therapy has not been elu-
cidated, although it is recommended to  continue therapy for at
least 7 days (C-II).
Document downloaded from http://www.elsevier.es, day 21/02/2018. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
F. Chaves et al. / Enferm Infecc Microbiol Clin. 2018;36(2):112–119 117
What is the recommended directed therapy and its optimal
duration for CRBSI due to Candida spp.?
Recommendations:
• In patients with Candida spp CRBSI, this panel advocates de-
escalation from an echinocandin or a  lipid formulation of
amphotericin B to fluconazole for susceptible isolates in clinically
stable patients who have undergone catheter removal (B-II).
• The recommended duration of therapy for candidemia without
obvious metastatic complications is  two weeks after the first set
of negative blood cultures (B-III).
• In candidemia, all intravascular catheters should be removed if
at all feasible (B-II), particularly in  patients with septic shock and
Candida CRBSI is suspected (B-III).
• If a catheter that is  the source of a  Candida bloodstream infection
cannot be removed for any reason and remains in place, an anti-
fungal agent with high activity against biofilms should be used
(i.e. an echinocandin or liposomal amphotericin B) (A-II).
What is the recommended directed therapy and its optimal
duration for CRBSI due to nontuberculous mycobacteria (NTM)?
Recommendations:
• The treatment for CRBSI caused by  NTM involves removal of the
infected catheter (B-II) followed by  combination antimicrobial
treatment appropriate for the species involved (B-III).
• The duration of treatment for NTM CRBSI should be  6–12 weeks
to prevent recurrence of infection and the development of septic
metastases (B-III).
Should antimicrobials for CRSBI be administered intra-
venously for the entire course of treatment?
Recommendations:
• Sequential oral therapy can be considered in clinically stable
patients without metastatic complications and with negative
blood cultures after onset of treatment and removal of the intra-
venous line, if  a  therapeutic option with high oral bioavailability
is available (A-II).
• In uncomplicated CRBSI caused by fluoroquinolone-susceptible
staphylococci, initial intravenous antibiotic treatment may  be
switched to high-dose oral fluoroquinolones plus rifampicin in
order to complete the course of antibiotic therapy if the patient
is clinically stable and clearance of bacteremia is  documented.
Linezolid could be an option if the microorganism involved is
fluorquinolone-resistant (A-II).
• In uncomplicated CRBSI caused by fluoroquinolone-susceptible
Gram-negative bacilli, initial intravenous antibiotic treatment
may be switched to high-dose oral fluoroquinolones in  order to
complete the course of antibiotic therapy if the patient is  clinically
stable and clearance of bacteremia is  documented (A-II).
• A step-down from an echinocandin or  lipid  formulation of
amphotericin B to oral fluconazole is safe and effective (C-III).
Conservative treatment: antibiotic lock therapy (ALT)
When is conservative management with antibiotic lock ther-
apy recommended?
Recommendation:
• Conservative treatment should not be prescribed for patients
with metastatic or local septic complications (A-II).
• The use of lock therapy added to systemic antimicrobial agents
is systematically recommended for infected catheters that fulfill
the criteria for catheter retention: the patient is stable and the
microorganism involved is considered to  be  of low virulence (i.e.
CoNS) (A-I).
• In stable patients without local or systemic complications, con-
servative treatment may  also be attempted for enterococci,
corynebacterium (except Corynebacterium jeikeium) and Gram-
negatives (consultation with an ID expert is  suggested in such
cases) (C-III).
• The use of an antibiotic lock does not preclude the need for sys-
temic antimicrobial therapy (A-I).
What antibiotics and concentrations of antibiotic lock solu-
tions are recommended?
Recommendation:
• The most frequently used antibiotics for conservative treat-
ment of CRBSI using ALT are vancomycin 2000 mg/L, teicoplanin
10,000 mg/L, daptomycin 5000 mg/L, ciprofloxacin 2000 mg/L,
and amikacin 2000 mg/L (B-I).
How should antibiotic lock therapy be performed?
Recommendation:
• An ALT solution should be prepared under sterile conditions. It
should be infused after removing the previous dose and the exact
volume of the catheter lumen should be infused. The recom-
mended duration of ALT is  10–14 days. The ALT solution must
remain in  the catheter lumen for a minimum of 12 h a  day and
should be replaced every 24–72 h (B-I).
What non-antibiotic substances could be used for lock ther-
apy?
Recommendations:
• 70% ethanol and taurolidine locks can also be used for the conser-
vative treatment of CRBSI. There is no evidence to advocate for
their routine use (B-I).
What are the criteria for failure of conservative manage-
ment?
Recommendation:
• Any clinical condition or catheter dysfunction prompting catheter
removal should be considered failure of conservative manage-
ment (A-I).
Management of local complications
How should insertion site infection be managed?
Recommendations:
• For peripheral venous catheters, catheter removal is  mandatory
if there is  local pain, induration, erythema or exudate (A-I).
• For non-tunneled CVCs, the presence of erythema or purulence at
the catheter insertion site requires immediate catheter removal
(B-II).
• For uncomplicated exit site infections with long-term catheters,
a conservative approach with topical antimicrobial agents should
first be attempted. In cases of topical treatment failure, systemic
antibiotics should be administered (B-III).
• Persistence of clinical signs of infection beyond 72 h of  conserva-
tive management requires removal of the catheter (B-II).
How should tunnelitis be managed?
Recommendations:
Document downloaded from http://www.elsevier.es, day 21/02/2018. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
118 F. Chaves et al. / Enferm Infecc Microbiol Clin. 2018;36(2):112–119
• Patients with tunnel infection not associated with a  hemodial-
ysis catheter require catheter removal, incision and drainage, if
indicated, and 7–10 days of systemic antimicrobial therapy in the
absence of concomitant bacteremia or  candidemia (A-II).
• For tunnelitis without fever in  hemodialysis catheters, systemic
antibiotic therapy may  be attempted first (A-II). In tunnel infec-
tion with fever, catheter removal is  the first therapeutic option
together with systemic antimicrobial therapy (A-II).
• In tunnelitis, conservative management is associated with higher
failure rates (B-II).
How should a  local infection associated with a  port reservoir
be managed?
Recommendations:
• In the presence of signs of local inflammation at a  port reser-
voir, the port must be removed, the affected tissue drained and
systemic antibiotic therapy started (A-II).
• If a conservative strategy is the only option, a combination of
systemic antibiotics and antibiotic lock  therapy should be pre-
scribed, bearing in mind that this approach is associated with a
high failure rate (B-II).
Patient follow-up
In which patients and when should a  follow-up blood culture
be taken?
Recommendations:
• Follow-up blood cultures should be taken from all patients with
S. aureus or Candida spp CRBSI (A-II).
• In patients with S. aureus CRBSI, we recommend that follow-
up blood cultures should be obtained every 72 h until the first
negative result (A-II).
• Control blood cultures in CRBSI due to Candida spp  should be
obtained every 48 h until the first negative blood culture (A-II).
• For other causative microorganisms of CRBSI and if catheter sal-
vage is attempted, follow-up blood cultures should be obtained
72 h after starting appropriate antibiotic therapy. If persistent
bacteremia is documented, catheter removal is required (B-II).
• It is not necessary to  routinely perform follow-up blood cultures
in patients with CRBSI due to  microorganisms other than S.  aureus
or  Candida spp if the catheter has been withdrawn (A-II).
When should echocardiography be performed?
Recommendations:
• TEE should be performed in the vast majority of patients with
Staphylococcus aureus bacteremia. TEE is not necessary or can
be delayed in patients without the following risk factors: pro-
longed bacteremia, hemodialysis, metastatic foci of infection,
IVDA, implantable CVC, intracardiac device, prosthetic valve, pre-
vious IE or cardiac structural abnormality (A-II).
• The need for TEE in episodes of CRBSI caused by  other pathogens
should be individualized. This panel considers that IE should be
ruled out in all  patients with persistent bacteremia (or fungemia)
(C-III). Enterococcus spp and Candida spp pathogens are associated
with a high risk of developing endocarditis.
What is the diagnosis and management for w?
Recommendation:
• Suppurative thrombophlebitis should be ruled out in  all episodes
of CRBSI with persistent bacteremia (A-II).
• Confirmed diagnosis, mainly by ultrasonography, should be fol-
lowed by catheter withdrawal, prolonged antibiotic treatment
and an individualized assessment of the need for anticoagulation
(A-II).
When can a new catheter be inserted?
Recommendation:
• Although there is  a  clear lack of scientific evidence, it seems advis-
able to  wait, if feasible, before placing a new catheter after an
episode of CRBSI. The waiting period should be determined by
the resolution of signs and symptoms. If a  patient urgently needs
vascular access, a  catheter should be  inserted without delay (C-
III).
• Insertion of a new catheter after a  diagnosis of CRBSI is always
possible if the patient’s clinical condition dictates the need for a
new vascular access (A-III).
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